Drug Information

Drug (ID: DG00013) and It's Reported Resistant Information

Name	Terbinafine
Synonyms	Bramazil; Lamasil; TerbiFoam; Terbina; Lamisil AT; Lamisil Tablet; Ternbinafine HCl; Lamasil (TN); Lamisil (TN); SF 86-327; Terbisil (TN); Zabel (TN); SF-86-327; Terbinafine (USAN/INN); Terbinafine [USAN:BAN:INN]; Lamisil, Terbinex, Corbinal, Zabel, Terbinafine; Terbinafine, SF-86-327, Lamisil, TBNF; (2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)-2-hepten-4-yn-1-amine; (2E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine; (E)-N-(6,6-dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride Click to Show/Hide
Indication	In total 2 Indication(s) Fungal infection [ICD-11: 1F29-1F2F] Approved [1] Nail/perionychium infection [ICD-11: EE12] Phase 2 [1]
Structure
Target	Candida Squalene epoxidase (Candi ERG1)	ERG1_CANAL	[1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula	C21H25N
IsoSMILES	CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21
InChI	1S/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3/b9-5+
InChIKey	DOMXUEMWDBAQBQ-WEVVVXLNSA-N
PubChem CID	1549008
ChEBI ID	CHEBI:9448
TTD Drug ID	D01AYJ
DrugBank ID	DB00857

Type(s) of Resistant Mechanism of This Drug

IDUE: Irregularity in Drug Uptake and Drug Efflux

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-01: Infectious/parasitic diseases

Click to Show/Hide the Resistance Disease of This Class

Candidosis [ICD-11: 1F23]

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Irregularity in Drug Uptake and Drug Efflux (IDUE)		Click to Show/Hide
Key Molecule: Pleiotropic ABC efflux transporter of multiple drugs CDR1 (CDR1)			[1]
Molecule Alteration	Deletion mutation	Deleteion	Molecule Info
Sensitive Disease	Recurrent oropharyngeal candidiasis [ICD-11: 1F23.6]		Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	Candida albicans strain DSY448		5476
Experiment for Molecule Alteration	PCR; Southern blotting analysis; Northern blottling analysis
Experiment for Drug Resistance	Growth differences between the different C. albicans strains assay
Mechanism Description	The delta cdr1 mutant was also hypersusceptible to other antifungal agents (terbinafine and amorolfine) and to different metabolic inhibitors (cycloheximide, brefeldin A, and fluphenazine).

References

Ref 1	Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother. 1996 Oct;40(10):2300-5. doi: 10.1128/AAC.40.10.2300.